Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

Dr. Reddy's Laboratories Ltd.(down 2.87 per cent), Biocon Ltd.(down 2.77 per cent), Sanofi India Ltd.(down 1.64 per cent), ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

The District 60 Board of Education unanimously approved a resolution hiring the Frantz Law Group Tuesday at the Lincoln Center administration building in Waukegan to help it recoup some of the ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

London-listed GSK Plc and France’s Sanofi SA saw similar declines, with Deutsche Bank analyst Emmanuel Papadakis cutting his ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...